EUVIMEDEUVIMED entdecken
Multizentrische Studie

Effectiveness and safety of apixaban and warfarin in patients with new- onset atrial fibrillation after advanced chronic kidney disease or end-stage kidney disease

Ming-Ju Wu, Hsin-Hua Chen, Cheng-Hsu Chen, Shang-Feng Tsai

Heart Rhythm · 2025

DOI: 10.1016/j.hrthm.2025.01.045 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Heart Rhythm, 2025. Verfasst von Ming-Ju Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Post-Baccalaureate Medic…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Warfarin, Pyridones, Pyrazoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Kaohsiung Veterans General Hospital, Taichung Veterans General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Limited evidence supports the use of apixaban for atrial fibrillation (AF) in patients with severe chronic kidney disease (CKD) or end-stage kidney disease (ESKD) when warfarin is often contraindicated. OBJECTIVE: Through an extensive cohort study, we attempted to compare the outcomes of apixaban and warfarin in patients within this population. METHODS: Using TriNetX data (2017-2023), we compared apixaban and warfarin in patients with chronic AF after stage 5 CKD or ESKD. Propensity score matching (PSM) and Cox multivariate analysis were applied to reduce bias. Only exclusive users were included to prevent switching influence. Subdistribution hazard ratios (SHRs) and 95% confidence intervals (CIs) for outcomes (cerebrovascular events, bleeding, and mortality) were adjusted for competing risks. Subgroup analyses considered sex, age, and dialysis status. We also compared apixaban doses to evaluate dose-related effects. RESULTS: After 1:1 PSM, our analysis included 1364 cases per group. The apixaban group showed significant advantages over the warfarin group in effectiveness (cerebral infarction: SHR 0.72; 95% CI 0.60-0.85; hemorrhagic stroke: SHR 0.42, 95% CI 0.28-0.63; cerebrovascular events: SHR 0.69, 95% CI 0.59-0.81), bleeding safety (gastrointestinal bleeding: SHR 0.77, 95% CI 0.61-0.97; blood transfusion: SHR 0.73, 95% CI 0.61-0.87; bleeding-related outcomes: SHR 0.75, 95% CI 0.64-0.87), and all composite outcomes (SHR 0.69, 95% CI 0.61-0.78). Subgroup analyses showed consistent improvements across gender, age, and dialysis status. Warfarin's time in therapeutic range was 44.4%. Sensitivity analysis still lacks sufficient evidence to determine whether the 5-mg or 2.5-mg dose of apixaban is superior. CONCLUSION: This large cohort study highlights the lower risks of cerebrovascular events and bleeding associated with apixaban in patients with stage 5 CKD or those undergoing hemodialysis. However, the optimal dosage of apixaban requires further investigation in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationWarfarinPyridonesPyrazolesKidney Failure, ChronicRenal Insufficiency, ChronicStrokeHumansMaleFemaleAgedFactor Xa InhibitorsAnticoagulantsRetrospective StudiesMiddle AgedTreatment OutcomeFollow-Up StudiesHemorrhage

Stichwörter der Autor:innen

ApixabanAtrial fibrillationChronic kidney diseaseDialysisEnd-stage kidney diseaseTriNetXWarfarin

Substanzen

apixabanWarfarinPyridonesPyrazolesFactor Xa InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, T…
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan; Institute of Biomedical Science and Rong Hsing Research Centre for Translational Medicine, Chung Hsing U…

Förderung

  • Kaohsiung Veterans General Hospital
  • Taichung Veterans General Hospital

Zitieren

APA

Wu, M. J., Chen, H. H., Chen, C. H., & Tsai, S. F. (2025). Effectiveness and safety of apixaban and warfarin in patients with new- onset atrial fibrillation after advanced chronic kidney disease or end-stage kidney disease. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2025.01.045

Vancouver

Wu MJ, Chen HH, Chen CH, Tsai SF. Effectiveness and safety of apixaban and warfarin in patients with new- onset atrial fibrillation after advanced chronic kidney disease or end-stage kidney disease. Heart Rhythm. 2025. doi:10.1016/j.hrthm.2025.01.045

BibTeX
@article{Wu2025,
  author = {Wu, Ming-Ju and Chen, Hsin-Hua and Chen, Cheng-Hsu and Tsai, Shang-Feng},
  title = {Effectiveness and safety of apixaban and warfarin in patients with new- onset atrial fibrillation after advanced chronic kidney disease or end-stage kidney disease},
  journal = {Heart Rhythm},
  year = {2025},
  doi = {10.1016/j.hrthm.2025.01.045}
}
Kostenlos starten →